Given that benign PTs display a significantly lower mutation burden than malignant PTs (Piscuoglio et al., 2016b) and lack mutations affecting bona fide cancer genes (Piscuoglio et al., 2016b; Tan et al., 2015), only MED12 remained significantly more frequently mutated in benign PTs than in adenosarcomas (83% vs 5%; Fisher's exact test, P = 0.0006; Fig. S2A). This evidence concerns the gene MED12 and cancer.